Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study

Autor: Saida, Takahiko, Kira, Jun-ichi, Kishida, Shuji, Yamamura, Takashi, Sudo, Yukiko, Ogiwara, Kazutaka, Tibung, JT, Lucas, Nisha, Subramanyam, Meena

Publikováno v: In Multiple Sclerosis and Related Disorders January 2017 11:25-31

Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial.

Autor: Saida T; Kansai Multiple Sclerosis Center, Kyoto, Japan. saida_takahiko@maia.eonet.ne.jp., Kira JI; Department of Neurology, Graduate School of Medical Sciences, Fukuoka, Japan., Kishida S; Hakusuikai Hatsuishi Hospital, Chiba, Japan., Yamamura T; National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan., Ohtsuka N; Biogen Japan, Chuo-ku, Tokyo, Japan., Ling Y; Biogen Japan, Chuo-ku, Tokyo, Japan., Torii S; Biogen Japan, Chuo-ku, Tokyo, Japan., Lucas N; Biogen, Cambridge, MA, USA., Kuesters G; Biogen, Cambridge, MA, USA., Steiner D; Biogen, Cambridge, MA, USA., Tibung JT; Biogen Japan, Chuo-ku, Tokyo, Japan.

Publikováno v: Neurology and therapy [Neurol Ther] 2017 Jun; Vol. 6 (1), pp. 39-55. Date of Electronic Publication: 2016 Dec 05.